NASDAQ:BMRN
BioMarin Pharmaceutical Inc. Stock News
$92.06
+2.57 (+2.87%)
At Close: Apr 23, 2024
BioMarin's (BMRN) Hemophilia Gene Therapy Gets Nod in EU
01:33pm, Thursday, 25'th Aug 2022
BioMarin's (BMRN) Roctavian is the first gene therapy to get approval for hemophilia A in the European Union. The therapy has also been granted a 10-year market exclusivity.
What's Next in Pfizer's M&A Ramp-Up?
12:23pm, Saturday, 20'th Aug 2022 The Motley Fool
Pfizer could be gearing up for a big acquisition.
Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal
03:39pm, Friday, 12'th Aug 2022 Zacks Investment Research
Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline
Roche (RHHBY) Influenza Drug Gets FDA Nod for Children
02:33pm, Friday, 12'th Aug 2022 Zacks Investment Research
Roche (RHHBY) obtains FDA approval for expanded indication of influenza drug Xofluza.
CRISPR Therapeutics (CRSP) Q2 Earnings & Sales Miss Estimates
01:05pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
CRISPR Therapeutics (CRSP) reports a wider-than-expected Q2 loss. Revenues also miss estimates.
Clearwater Paper and Logitech International have been highlighted as Zacks Bull and Bear of the Day
12:23pm, Monday, 08'th Aug 2022 Zacks Investment Research
Clearwater Paper and Logitech International are part of as Zacks Bull and Bear of the Day article.
There are three reasons health care is the market's best sector today. These eight stocks are the most worry-free.
02:22pm, Saturday, 06'th Aug 2022 MarketWatch
Health-care stocks have both growth and defensive characteristics.
Expert Ratings for Biomarin Pharmaceutical
03:11pm, Thursday, 04'th Aug 2022 Benzinga
Within the last quarter, Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
5
1
0
BioMarin's (BMRN) Q2 Earnings Top, Voxzogo Drives Sales
11:31am, Thursday, 04'th Aug 2022 Zacks Investment Research
Biomarin Pharmaceutical's (BMRN) second-quarter earnings and sales beat estimates. BMRN slightly raises its sales guidance for the year.
BioMarin's (BMRN) Q2 Earnings Top, Voxzogo Drives Sales
09:02am, Thursday, 04'th Aug 2022
Biomarin Pharmaceutical's (BMRN) second-quarter earnings and sales beat estimates. BMRN slightly raises its sales guidance for the year.
BioMarin Pharmaceutical Inc. (BMRN) CEO J.J. Bienaime on Q2 2022 Results - Earnings Call Transcript
12:40am, Thursday, 04'th Aug 2022
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Traci McCarty - Vice President of Investor Relations J.J. Bienaime - Chairma
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
09:15pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
BioMarin (BMRN) delivered earnings and revenue surprises of 37.21% and 3.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
06:48pm, Wednesday, 03'rd Aug 2022
BioMarin (BMRN) delivered earnings and revenue surprises of 37.21% and 3.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
These eight health-care stocks can keep you invested in the market with less worry
10:52am, Tuesday, 02'nd Aug 2022
You're tempted to increase exposure to stocks because of the market's strength. But you're still gun shy because of the painful selloff.
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: Should You Buy?
02:02pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Mirum Pharmaceuticals, Inc. (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
